US Patent

US8865710 — Methods of treating proliferative diseases

Formulation · Assigned to Ambit Bioscience Corp · Expires 2029-08-15 · 3y remaining

Vulnerability score 56/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of administering quizartinib dihydrochloride to treat proliferative diseases or FLT-3 mediated diseases in humans.

USPTO Abstract

Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
US8865710
Jurisdiction
US
Classification
Formulation
Expires
2029-08-15
Drug substance claim
No
Drug product claim
Yes
Assignee
Ambit Bioscience Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.